Peptron Inc - Asset Resilience Ratio

Latest as of September 2025: 57.41%

Peptron Inc (087010) has an Asset Resilience Ratio of 57.41% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read debt load of Peptron Inc for a breakdown of total debt and financial obligations.

Liquid Assets

₩105.49 Billion
≈ $71.49 Million USD Cash + Short-term Investments

Total Assets

₩183.74 Billion
≈ $124.52 Million USD All company assets

Resilience Assessment

Very High
Financial Resilience Level

Asset Resilience Ratio Trend (2014–2024)

This chart shows how Peptron Inc's Asset Resilience Ratio has changed over time. See 087010 book value for net asset value and shareholders' equity analysis.

Liquid Assets Composition Over Time

This chart breaks down Peptron Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see market cap of Peptron Inc.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents ₩0.00 0%
Short-term Investments ₩105.49 Billion 57.41%
Total Liquid Assets ₩105.49 Billion 57.41%

Asset Resilience Insights

  • Very High Liquidity: Peptron Inc maintains exceptional liquid asset reserves at 57.41% of total assets.
  • This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
  • The company has significant short-term investments, indicating active treasury management.

Peptron Inc Industry Peers by Asset Resilience Ratio

Compare Peptron Inc's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Pluristem
TA:PSTI
Biotechnology & Medical Research 48.26%
Hadasit Bio
TA:HDST
Biotechnology & Medical Research 57.00%
Purple Biotech Ltd
TA:KTOV
Biotechnology & Medical Research 0.01%
MEDIPOST Co. Ltd
KQ:078160
Biotechnology & Medical Research 0.72%
Bioneer Corporation
KQ:064550
Biotechnology & Medical Research 14.92%
Macrogen Inc
KQ:038290
Biotechnology & Medical Research 3.56%
Cell Biotech Co. Ltd
KQ:049960
Biotechnology & Medical Research 54.84%
Panagene Inc
KQ:046210
Biotechnology & Medical Research 0.14%

Annual Asset Resilience Ratio for Peptron Inc (2014–2024)

The table below shows the annual Asset Resilience Ratio data for Peptron Inc.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2024-12-31 72.74% ₩122.85 Billion
≈ $83.25 Million
₩168.89 Billion
≈ $114.46 Million
+71.37pp
2023-12-31 1.37% ₩718.34 Million
≈ $486.81K
₩52.50 Billion
≈ $35.58 Million
-23.89pp
2022-12-31 25.26% ₩17.24 Billion
≈ $11.69 Million
₩68.27 Billion
≈ $46.27 Million
-13.57pp
2021-12-31 38.83% ₩30.24 Billion
≈ $20.49 Million
₩77.87 Billion
≈ $52.77 Million
-21.15pp
2020-12-31 59.98% ₩70.59 Billion
≈ $47.84 Million
₩117.70 Billion
≈ $79.76 Million
+31.21pp
2019-12-31 28.77% ₩17.55 Billion
≈ $11.89 Million
₩60.99 Billion
≈ $41.33 Million
-8.57pp
2018-12-31 37.34% ₩26.80 Billion
≈ $18.16 Million
₩71.76 Billion
≈ $48.63 Million
+6.92pp
2017-12-31 30.42% ₩16.14 Billion
≈ $10.94 Million
₩53.05 Billion
≈ $35.95 Million
-31.32pp
2016-12-31 61.75% ₩35.75 Billion
≈ $24.23 Million
₩57.90 Billion
≈ $39.24 Million
+61.31pp
2015-12-31 0.43% ₩94.00 Million
≈ $63.70K
₩21.66 Billion
≈ $14.68 Million
-0.38pp
2014-12-31 0.81% ₩94.00 Million
≈ $63.70K
₩11.58 Billion
≈ $7.84 Million
--
pp = percentage points

About Peptron Inc

KQ:087010 Korea Biotechnology & Medical Research
Market Cap
$2.71 Billion
₩3.99 Trillion KRW
Market Cap Rank
#5248 Global
#129 in Korea
Share Price
₩260500.00
Change (1 day)
-3.52%
52-Week Range
₩157300.00 - ₩386000.00
All Time High
₩386000.00
About

Peptron, Inc. engages in the development of peptide-based medicines. The company's technologies include long acting; and SmartDepot, an ultrasonic spray drying technology for the preparation of sustained release injectable microsphere formulation of drug. Its research and development products include Luphere Depot for prostate cancer, endometriosis, uterine fibroids, premenopausal breast cancer, … Read more